BioCryst Reports Third-Quarter Revenue of $180.3 Million
Third-quarter 2026 revenue rose 13.1% year over year to $180.3 million. Net income was $37.9 million versus $12.9 million, and diluted EPS was $0.14 versus $0.06.
Third-quarter 2026 revenue rose 13.1% year over year to $180.3 million. Net income was $37.9 million versus $12.9 million, and diluted EPS was $0.14 versus $0.06.